March 1, 2012
At a meeting on February 29, the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)’s Second Committee on Drugs recommended approval for Pfizer Japan’s Xalkori Capsule 200 mg, 250 mg (crizotinib) for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small...read more